In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)
In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER. The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which Endo paid Impax more than $100 million to delay launching a less-expensive generic version of Opana ER.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
685 Third Avenue 26th Floor
10017 New York, New York
Joseph T. Lukensjlukens@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Peter Kohnpkohn@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
685 Third Avenue 26th Floor New York, New York10017 (212) 983-9330 (877) 247-4292 (212) 983-9331
10866 Wilshire Boulevard Suite 1470 Los Angeles, California90024 (424) 256-2884 (424) 256-2885